^
Association details:
| Biomarker: | Chr amplification(1)(q21) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | pomalidomide (TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor) + Sarclisa (isatuximab-irfc) (CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
Published date:
05/25/2021
Excerpt:
Improved mPFS in the isatuximab group versus control group was observed both in patients with isolated 1q21 amplification (≥4 copies 1q21; 8·9 vs 2·3 months; HR, 0·55; 95% CI, 0·21–1·43;...Isatuximab–pomalidomide–dexamethasone provides a consistent benefit over pomalidomide–dexamethasone treatment in RRMM patients...
DOI:
https://doi.org/10.1111/bjh.17499
Trial ID:
